Table 2.

INTERCheck^® scores (total and divided in risk classes A, B, C, D, C + D, ACB) in outpatients (n = 98) and inpatients (n = 46) without (n = 25) and with (n = 21) severe ADEs

	Total score	Class					ACB
		A	B	C	D	C + D
Outpatients	4.5 ± 3.8	0.1 ± 0.3	3.2 ± 3.8	0.8 ± 1.2	0.3 ± 0.6	1.1 ± 1.6	0.9 ± 1.3
Inpatients	5.2 ± 4.8	0.1 ± 0.3	3.0 ± 2.9	1.1 ± 1.5	0.9 ± 1.6	2.0 ± 2.5	2.2 ± 2.1
Inpatients without severe ADEs	2.9 ± 2.6	0.0 ± 0.0	2.2 ± 2.0	0.4 ± 0.6	0.4 ± 0.9	0.8 ± 1.4	1.6 ± 1.7
Inpatients with severe ADEs	7.9 ± 5.3	0.3 ± 0.5	4.1 ± 3.4	2.0 ± 1.9	1.6 ± 2.0	3.6 ± 2.8	2.9 ± 2.4

Outpatients vs. total inpatients class D p = 0.01, class C + D p = 0.025, ACB p = 0.00001; inpatients with vs. without severe ADEs, INTERCheck^® total score p = 0.001, class A p = 0.01, class B p = 0.025, class C p = 0.001, class D p = 0.01, class C + D p = 0.00001, ACB p = 0.05; inpatients with severe ADEs vs. outpatients INTERCheck^® total score p = 0.001, class A p = 0.025, class C p = 0.0001, class D p < 0.000001, class C + D p < 0.000001, ACB p < 0.000001. The INTERCheck^® software describes the interactions between drugs according to their clinical relevance in class A (minor, no known clinical relevance), class B (moderate, interaction associated with an uncertain or variable event), class C (major, interaction associated with a serious event, but which can be managed, e.g., by reducing the dose), and class D (contraindicated or very serious interaction associated with a serious event for which it is appropriate to avoid coadministration or to establish careful monitoring). Data are presented as mean ± standard deviation

ACB anticholinergic cognitive burden scale, ADE adverse drug event